Management Report & Annexes | Report on Economic Position

16.4 Value Management

System based on cash value added

The principal value-based steering parameters in the Bayer Group are the cash value added (cva) and the cash flow return on investment (cfroi). If the cva is positive, the respective company or business entity has exceeded the minimum requirements of the equity and debt capital providers and has created value. The cfroi is a ratio indicating the profitability of the Group or of individual business entities and must be compared to the cost of capital.

Calculating the cost of capital

Bayer calculates the cost of capital according to the debt/equity ratio at the beginning of the year using the weighted average cost of capital (wacc) formula. The cost of equity capital is the return expected by stockholders, computed from capital market information. The cost of debt capital used in calculating wacc is based on the terms for ten-year Eurobonds issued by industrial companies with an “a-” rating.

To take into account the different risk and return profiles of our principal businesses, we calculate individual capital cost factors after income taxes for each of our subgroups. These were 7.9% for HealthCare, 7.3% for CropScience and 6.9% for MaterialScience. The capital cost factor for the Group as a whole in 2014 was 7.6%.

Gross cash flow, cash value added and cash flow return on investment as performance yardsticks

The gross cash flow is the measure of our internal financing capability. Bayer has chosen this parameter because it is relatively free of accounting influences and is therefore a more meaningful performance indicator.

Taking into account the costs of capital and of reproducing depletable assets, we determine the gross cash flow hurdle. If the gross cash flow hurdle is exceeded, the cva is positive and thus the required return on equity and debt plus the cost of asset reproduction has been earned.

The cfroi is the difference between the gross cash flow and the cost of reproducing depletable assets, divided by the capital invested. The capital invested is calculated from the statement of financial position and basically comprises the property, plant and equipment and intangible assets required for operations – stated at the historical cost of acquisition or construction – plus working capital, less interest-free liabilities (such as current provisions). To mitigate the effect of fluctuations in the capital invested during the year, the cfroi is computed on the basis of the average capital invested for the respective year.

The gross cash flow hurdle for 2014 was €4,447 million.

Actual gross cash flow came in at €6,820 million, exceeding the hurdle by 53.4%. Thus the entire cost of capital and asset reproduction costs were earned in 2014. The positive cva of €2,373 million shows that Bayer exceeded the minimum return and reproduction requirements and created value. A cfroi of 11.9% was achieved in 2014

HealthCare and CropScience exceeded their required returns (including asset reproduction), raised their cva and helped to increase the value of the Group. In 2014 MaterialScience reduced the gap to the gross cash flow hurdle, which continues to be impacted by growth investments.

Value Management Indicators by Subgroup           [Table 3.16.4]
  HealthCare CropScience MaterialScience Bayer Group
  2013 2014 2013 2014 2013 2014 2013 2014
  € million € million € million € million € million € million € million € million
Gross cash flow1 (GCF) 3,573 4,011 1,590 1,835 887 961 5,832 6,820
Gross cash flow hurdle 2,109 2,395 906 902 1,060 1,025 4,260 4,447
Cash value added (CVA) 1,464 1,616 684 933 (173) (64) 1,572 2,373
Cash flow return on investment (CFROI) 14.1% 13.4% 14.2% 15.3% 5.5% 6.0% 11.1% 11.9%
WACC 7.9% 7.9% 7.3% 7.3% 6.9% 6.9% 7.6% 7.6%
Average capital invested 22,480 26,784 9,881 10,841 10,371 10,524 43,548 48,934
Delta cash value added is not listed due to its limited importance.
1 For definition see Chapter 16.5 “Liquidity and Capital Expenditures of the Bayer Group.”
Last updated: February 26, 2015  Copyright © Bayer AG
http://www.annualreport2014.bayer.com